Novo released full results showing its Wegovy injection helped children ages 6 to under 12 with obesity lose weight. At 68 weeks, Wegovy reduced BMI by an estimated 19.7 percentage points more than placebo among children who stayed on treatment. BMI fell 17.4% among children receiving the drug and rose 2.2% among those on placebo.

When including all 167 children in the study, including those who stopped treatment, Wegovy lowered BMI by an estimated 16.2 percentage points more than placebo at 68 weeks. All children received lifestyle modifications including a reduced-calorie diet and increased physical activity.

More than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks, assuming they stayed on treatment.

Wegovy is already approved for children ages 12 and older. No medications are currently approved for obesity treatment in children under 12. In the trial, 85% of children started with moderate to severe obesity, and nearly half had at least one obesity-related complication such as high blood pressure, high cholesterol, or sleep apnea.

Novo said Wegovy's safety and tolerability in children matched what was seen in adult trials. The company observed no safety concerns related to growth or pubertal development.

Dr. Andrea Traina, Novo's medical director lead of obesity, noted that the two-year study does not establish whether treating obesity earlier can change its long-term trajectory. "That is something that is still an evidence gap," she said.